Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:INFI
- CUSIP: 45665G30
- Web: www.infi.com
Capitalization:- Market Cap: $58.8 million
- Outstanding Shares: 50,690,000
Average Prices:- 50 Day Moving Avg: $1.15
- 200 Day Moving Avg: $1.83
- 52 Week Range: $0.84 - $3.84
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.77
- P/E Growth: -0.01
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.17 per share
- Price / Book: 0.99
Profitability:- EBIDTA: ($55,730,000.00)
- Return on Equity: -88.08%
- Return on Assets: -59.20%
Debt:- Debt-to-Equity Ratio: 0.35%
- Current Ratio: 6.29%
- Quick Ratio: 6.29%
Misc:- Average Volume: 773,291 shs.
- Beta: 2.65
- Short Ratio: 4
Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its earnings results on Thursday, August, 3rd. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.12. During the same period in the prior year, the business earned $1.05 earnings per share. View Infinity Pharmaceuticals' Earnings History.
When will Infinity Pharmaceuticals make its next earnings announcement?
Are investors shorting Infinity Pharmaceuticals?
Infinity Pharmaceuticals saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 908,639 shares, a decrease of 22.5% from the August 15th total of 1,172,061 shares. Based on an average daily trading volume, of 658,966 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.9% of the company's shares are short sold.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Matinas BioPharma Holdings (MTNB), CASI Pharmaceuticals (CASI), BioLineRx (BLRX), CTI BioPharma Corp. (CTIC), aTyr Pharma (LIFE), Palatin Technologies (PTN), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Vernalis plc (VER), Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT) and ReNeuron Group Plc (RENE).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer
- Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer
- William C. Bertrand Jr. Esq., Executive Vice President, General Counsel
- Melissa Hackel, Vice President - Finance
- Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
- Norman C. Selby, Lead Outside Independent Director
- Jeffrey Berkowitz J.D., Independent Director
- Anthony B. Evnin Ph.D., Independent Director
- Michael G. Kauffman M.D., Ph.D., Independent Director
- Ian F. Smith CPA, Independent Director
Who owns Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.17%), Pinnacle Associates Ltd. (2.47%), Platinum Investment Management Ltd. (1.60%), Dimensional Fund Advisors LP (1.29%), Northern Trust Corp (0.75%) and State Street Corp (0.72%). Company insiders that own Infinity Pharmaceuticals stock include Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Acadian Asset Management LLC, Northern Trust Corp, Russell Investments Group Ltd., Vanguard Group Inc., Pinnacle Associates Ltd. and Nationwide Fund Advisors. Company insiders that have sold Infinity Pharmaceuticals stock in the last year include Michael C Venuti and Sujay Kango. View Insider Buying and Selling for Infinity Pharmaceuticals.
Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Legal & General Group Plc, FMR LLC, Dimensional Fund Advisors LP, LMR Partners LLP, Goldman Sachs Group Inc., Ameriprise Financial Inc. and Zacks Investment Management. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy Infinity Pharmaceuticals stock?
Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.16.
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ INFI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.20) | | | | | N/A |  |
| 8/3/2017 | Q2 2017 | ($0.22) | ($0.34) | | | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.22) | ($0.21) | $19.60 million | $0.01 million | View | Listen | |
| 3/14/2017 | Q4 2016 | ($0.57) | ($0.46) | $2.33 million | | View | N/A | |
| 11/9/2016 | Q316 | ($0.84) | ($0.39) | $6.23 million | | View | Listen | |
| 8/9/2016 | Q216 | ($0.89) | $1.05 | $13.91 million | $9.47 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.82) | ($0.82) | $8.80 million | $9.26 million | View | Listen | |
| 2/23/2016 | Q415 | ($0.72) | ($0.80) | $18.26 million | $9.10 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.76) | $0.84 | $24.85 million | $90.70 million | View | N/A | |
| 8/6/2015 | Q215 | ($1.00) | ($0.78) | $5.83 million | $4.90 million | View | N/A | |
| 5/6/2015 | Q115 | ($1.69) | ($1.91) | $5.79 million | $4.40 million | View | Listen | |
| 2/24/2015 | Q414 | ($0.99) | ($0.83) | $5.61 million | $4.36 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.87) | $2.03 | $141.40 million | $160.60 million | View | Listen | |
| 8/5/2014 | Q114 | ($0.84) | ($0.78) | | | View | N/A | |
| 5/6/2014 | Q1 | ($0.80) | ($0.87) | | | View | Listen | |
| 2/25/2014 | Q413 | ($0.87) | ($0.68) | | | View | Listen | |
| 11/7/2013 | | ($0.75) | ($0.71) | | | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.62) | ($0.68) | | | View | Listen | |
| 11/6/2012 | Q312 | ($0.57) | $0.52 | $13.90 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)2017 EPS Consensus Estimate: ($0.69)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.23) | ($0.13) | ($0.18) |
| Q2 2017 | 2 | ($0.21) | ($0.12) | ($0.17) |
| Q3 2017 | 2 | ($0.21) | ($0.13) | ($0.17) |
| Q4 2017 | 2 | ($0.21) | ($0.13) | ($0.17) |
(Data provided by Zacks Investment Research)
Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 67.47%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/17/2017 | Michael C Venuti | Director | Sell | 6,250 | $3.48 | $21,750.00 | |
| 1/3/2017 | Value Fund L P Biotechnology | Major Shareholder | Buy | 4,379 | $1.34 | $5,867.86 | |
| 12/30/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 742,401 | $1.34 | $994,817.34 | |
| 12/20/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 654,921 | $1.31 | $857,946.51 | |
| 12/13/2016 | Sujay Kango | Insider | Sell | 75,000 | $1.28 | $96,000.00 | |
| 12/12/2016 | Sujay Kango | Insider | Sell | 25,009 | $1.30 | $32,511.70 | |
| 12/2/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 201,394 | $1.19 | $239,658.86 | |
| 6/25/2015 | Adelene Q Perkins | CEO | Sell | 5,000 | $10.93 | $54,650.00 | |
| 6/15/2015 | Vito J Palombella | Insider | Sell | 4,737 | $10.97 | $51,964.89 | |
| 5/27/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.81 | $128,100.00 | |
| 5/14/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.18 | $121,800.00 | |
| 3/16/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $16.00 | $320,000.00 | |
| 1/29/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $14.83 | $296,600.00 | |
| 12/15/2014 | Vito J Palombella | Insider | Sell | 4,737 | $16.32 | $77,307.84 | |
| 11/26/2014 | Vito J Palombella | Insider | Sell | 4,736 | $15.00 | $71,040.00 | |
| 9/30/2014 | Anthony B Evnin | Director | Sell | 112,451 | $13.56 | $1,524,835.56 | |
| 9/3/2014 | Vito J Palombella | Insider | Sell | 9,472 | $15.39 | $145,774.08 | |
| 11/27/2013 | Anthony B Evnin | Director | Sell | 163,864 | $14.82 | $2,428,464.48 | |
| 9/13/2013 | Adelene Perkins | CEO | Sell | 45,000 | $20.72 | $932,400.00 | |
| 6/20/2013 | Vito J Palombella | Insider | Sell | 23,150 | $18.53 | $428,969.50 | |
| 11/26/2012 | Christopher M Lindblom | Insider | Sell | 13,885 | $25.73 | $357,261.05 | |
| 9/7/2012 | Co Beacon | Major Shareholder | Buy | 5,416,565 | $14.50 | $78,540,192.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
| Source: |
|
| Date | Headline |
|---|
 | Infinity Pharmaceuticals, Inc. (INFI) Short Interest Update
www.americanbankingnews.com - September 17 at 1:20 AM |
| Financial Analysis: Infinity Pharmaceuticals (INFI) vs. RXi Pharmaceuticals Corporation (RXII)
www.americanbankingnews.com - September 10 at 6:26 PM |
| Infinity Pharmaceuticals, Inc. (INFI) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 5 at 6:14 AM |
| Infinity Pharmaceuticals, Inc. (INFI) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 AM |
| -$0.21 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter
www.americanbankingnews.com - August 17 at 8:26 PM |
 | Infinity (INFI) Q2 Loss Wider than Expected, View Intact - Nasdaq
www.nasdaq.com - August 6 at 4:44 AM |
 | Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 4:44 AM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 8:22 PM |
 | Edited Transcript of INFI earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 8:10 PM |
| Infinity (INFI) Q2 Loss Wider than Expected, View Intact
finance.yahoo.com - August 4 at 8:10 PM |
 | BRIEF-Infinity Q2 loss per share $0.34
www.reuters.com - August 3 at 8:00 PM |
| Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:00 PM |
| Infinity reports 2Q loss
finance.yahoo.com - August 3 at 8:00 PM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 12:34 PM |
 | Infinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda
www.streetinsider.com - July 29 at 6:49 PM |
| Infinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda - StreetInsider.com
www.streetinsider.com - July 28 at 3:41 AM |
| Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
finance.yahoo.com - July 27 at 10:40 PM |
| Financial Survey: Celator Pharmaceuticals (CPXX) versus Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - July 21 at 6:06 PM |
| Infinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - July 21 at 3:58 PM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - July 8 at 11:26 PM |
| Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 7 at 12:44 PM |
 | Company Spotlight: Verastem
www.rttnews.com - July 7 at 6:29 AM |
| Zacks: Brokerages Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - July 6 at 10:30 AM |
| ValuEngine Upgrades Infinity Pharmaceuticals, Inc. (INFI) to Sell
www.americanbankingnews.com - June 15 at 8:50 PM |
 | Infinity to Participate in Three Upcoming Conferences - PR Newswire (press release)
www.prnewswire.com - June 15 at 6:13 AM |
| Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - June 14 at 11:23 AM |
| Infinity to Participate in Three Upcoming Conferences
finance.yahoo.com - June 14 at 11:23 AM |
| Infinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 10:55 AM |
| Infinity Pharmaceuticals Inc. (INFI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 12 at 12:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - June 12 at 10:24 AM |
| Infinity Pharmaceuticals Inc. (INFI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM |
| Infinity Pharmaceuticals Inc. (INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 16 at 2:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 1:34 PM |
| Infinity Pharmaceuticals Inc. (INFI) Short Interest Update
www.americanbankingnews.com - May 13 at 7:20 AM |
| Q2 2017 Earnings Forecast for Infinity Pharmaceuticals Inc. (INFI) Issued By William Blair
www.americanbankingnews.com - May 12 at 9:37 AM |
 | Verastem Reports First Quarter 2017 Financial Results
www.businesswire.com - May 10 at 6:21 PM |
| Edited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 6:21 PM |
| Infinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - May 10 at 1:18 PM |
| Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 10 at 1:18 PM |
| Infinity Pharmaceuticals Inc. (INFI) Posts Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 9:22 PM |
 | Infinity reports 1Q loss
marketbeat.com - May 9 at 5:44 PM |
| BRIEF-Infinity reports Q1 loss per share $0.21
www.reuters.com - May 9 at 5:43 PM |
| Infinity Provides Company Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:43 PM |
| Investor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:23 PM |
| Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
finance.yahoo.com - May 9 at 12:23 PM |
| Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session
finance.yahoo.com - May 8 at 7:29 AM |
| Verastem Boosts Oncologic Drug Portfolio, Fuels Stock Price
seekingalpha.com - May 7 at 6:18 PM |
| Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
www.nasdaq.com - May 4 at 6:05 PM |
| Infinity Pharmaceuticals (INFI) Earning Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 3 at 10:36 AM |
| Infinity Pharmaceuticals (INFI) Earning Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 11:50 PM |
Infinity Pharmaceuticals (INFI) Chart for Wednesday, September, 20, 2017
